Highly Specialised Technologies (HSTs)
HSTs evaluate single technologies within a single condition where the number of patients with the condition in England is small. The company provides a submission detailing the clinical effectiveness and estimating the cost-effectiveness of the intervention.
SCHARR-TAG critiques the company’s submission and mathematical model and provides the NICE appraisal committee with exploratory analyses and corresponding cost-effectiveness values.
2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2014
2024
Pegzilarginase for treating arginase-1 deficiency [ID4029].
2023
2022
Velmanase alfa for treating alpha-mannosidosis [ID800].
2021
Odevixibat for progressive familial intrahepatic cholestasis [ID1570].
2019
Volanesorsen for treating familial chylomicronaemia syndrome [ID1326].
2018
Patisiran for treating hereditary transthyretin-related amyloidosis [ID1279].
Recombinant human alpha-mannosidase for treating alpha-mannosidosis [ID800].
2014
Atypical haemolytic uraemic syndrome (aHUS) - eculizumab [HST1] (ID703)